Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cardiotoxicity × dapagliflozin × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Inflammation 1 Hyperinsulinism 1 Hyperglycemia 1 Hereditary Sensory and Autonomic Neuropathies 1 Heart Failure 1 Cardiotoxicity 1

Interventions

Trastuzumab 6 Exercise 6 Doxorubicin 6 Echocardiography 4 Cyclophosphamide 4 Carvedilol 4 Docetaxel 3 Tablets 2 Magnetic Resonance Spectroscopy 2 Bisoprolol 2 Atorvastatin 2 Anthracyclines 2 sacubitril and valsartan sodium hydrate drug combination 1 nicotinamide-beta-riboside 1 mitoquinone 1 epicatechin gallate 1 empagliflozin 1 dapagliflozin 1 candesartan 1 Watchful Waiting 1 Therapeutics 1 Social Determinants of Health 1 Silymarin 1 Secondary Prevention 1 Rosuvastatin Calcium 1 Reverse Transcriptase Polymerase Chain Reaction 1 Restraint, Physical 1 Rehabilitation 1 Ramipril 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06341842 2024-04-02

PROTECT

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase 2 Recruiting

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡